Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.77 |
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.67 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082016 | 0.88 | EGLN3 (0.60) | EGLN3EGLN1 | |
| SCHEMBL1080932 | 0.87 | EGLN3 (0.75) | EGLN3EGLN1NR1H4 | |
| SCHEMBL13620662 | 0.87 | EGLN3 (1.00) | EGLN3EGLN1 | |
| SCHEMBL1165374 | 0.86 | EGLN3 (0.58) | EGLN3EGLN1NR1H4 | |
| SCHEMBL1080635 | 0.84 | EGLN3 (0.71) | EGLN3EGLN1NR1H4 | |
| SCHEMBL1081707 | 0.84 | EGLN3 (0.74) | EGLN3EGLN1NR1H4 | |
| SCHEMBL1080231 | 0.84 | EGLN3 (0.55) | EGLN3EGLN1NR1H4 | |
| SCHEMBL1080241 | 0.82 | EGLN3 (1.00) | EGLN3EGLN1 | |
| SCHEMBL1081805 | 0.81 | EGLN1 (0.69) | EGLN3EGLN1NR1H4 | |
| SCHEMBL1082192 | 0.79 | EGLN3 (0.66) | EGLN3EGLN1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | claimed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | claimed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885NR1H4 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.